Research and Markets: Metastatic Ovarian Cancer Pipeline Review, H2 2015 – 9 Companies & 13 Drug Profiles

DUBLIN–(BUSINESS WIRE)–Research and Markets (
has announced the addition of the “Metastatic
Ovarian Cancer – Pipeline Review, H2 2015”
report to their

This report provides comprehensive information on the therapeutic
development for Metastatic Ovarian Cancer, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Metastatic Ovarian Cancer and special features on late-stage and
discontinued projects.

The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Cellceutix Corporation
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • Millennium Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Northwest Biotherapeutics, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • VG Life Sciences, Inc.

Drug Profiles

  • DCVax-Direct
  • DCVax-L
  • Drugs for Metastatic Ovarian Cancer
  • E-7449
  • emactuzumab
  • G-305
  • hydroxychloroquine + sorafenib tosylate
  • KM-3174
  • LV-305
  • NRCAN-019
  • orteronel
  • SM-276001
  • Vaccine for Oncology

For more information visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology,
, Ovarian